Aldeyra Therapeutics Inc.

(ALDX) Trade

By |

Profile

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye diseases, allergic conjunctivities, noninfectious anterior uveitis, and Sjogren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal disease, post-transplant lymphoproloferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

Contact Information

Website: www.aldeyra.com
Email: dburke@theruthgroup.com
Main Phone: +1 781 761-4904
Address: 131 Hartwell Avenue
Address 2: Suite 320
State: MA
City / Town: Lexington
Country: USA
Postal Code: 02421

Issuer Information

Exchange: NSC
CEO: Todd C. Brady
Employees: 20
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait

Profile

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye diseases, allergic conjunctivities, noninfectious anterior uveitis, and Sjogren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal disease, post-transplant lymphoproloferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

Contact Information

Website: www.aldeyra.com
Email: dburke@theruthgroup.com
Main Phone: +1 781 761-4904
Address: 131 Hartwell Avenue
Address 2: Suite 320
State: MA
City / Town: Lexington
Country: USA
Postal Code: 02421

Issuer Information

Exchange: NSC
CEO: Todd C. Brady
Employees: 20
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 5.10 $ 0.10 (2.00%)
Last Price 5.10 Change $ 0.10 Change % 2.00 Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open 4.97 High 5.12 Low 4.94 Prev Close 5.00
Last Trade Volume 43,759 52 Wk Hi 16.70 52 Wk Low 4.75
Market Cap 140.6 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 27,578,247.00 EPS (TTM) -1.98 PE Ratio N/A Exchange NCM
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 4
Number of Buys 0 4
Number of Sells 0 0
Net Activity 0 111273
Last 10 Buys Shares
Richard Douglas 1,000
Stephen Tulipano 1,000
Todd C. Brady 1,000
Martin J. Joyce 1,000
Ben Bronstein 1,000
Edelman Joseph 1,000
Edelman Joseph 1,000
C. Boyd Clarke 1,000
Martin J. Joyce 1,000
Gary M. Phillips 1,000
Last 10 Sell Shares
N/A 0
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 27 27 27 27
Low Target Price Estimate 13 13 13 13
Mean Target Price Estimate 19.75 19.75 19.75 19.75
Standard Deviation 6.4 6.4 6.4 6.4
Date of Most Recent Estimate 05/22/18 05/22/18 05/22/18 05/22/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 4 4 4 5
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1 1